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Abstract
A simple high‐performance liquid chromatography method for the determination of
hydromorphone in small volume plasma has been developed. Following solid‐phase
extraction using Oasis HLB cartridges, samples were separated by reverse‐phase
high‐performance liquid chromatography on an Atlantis T3 4.6 × 150mm column
(3.0μm) and quantified using mass spectrometry. The mobile phase was a mixture
of water with 0.1% formic acid and acetonitrile with 0.1% formic acid (91:9). The stan-
dard curve ranged from 1 to 500ng/mL. Intra‐ and Inter‐assay variability for
hydromorphone was <10%, and the average recovery was >90%. The LLOQ was
1 ng/mL. This method was successfully applied to the analysis of hydromorphone
samples at this institution. This method could be useful to those investigators dealing
with small sample volumes, particularly when conducting pharmacokinetic studies
that require multiple sampling from the same animal.
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1 | INTRODUCTION
Recognition of pain and appropriate analgesic therapy is becoming
increasingly important in veterinary medicine. Opioids are a diverse
group of drugs that bind to specific receptors in the brain, spinal
cord, and peripheral tissues. They are used for their analgesic prop-
erties, acting on the μ‐, κ‐ and δ‐opioid receptors in the central
nervous system and peripheral nervous system (Lamount &
Mathews, 2007). Hydromorphone is a semi‐synthetic μ‐opioid
receptor agonist with a potency 5–7 times that of morphine
(Murray & Hagen, 2005). Extensive research studies support the
clinical use of hydromorphone in pain management protocols (Kelly,
Pypendop, & Christe, 2014). It is used frequently in the USA in
small animal anesthesia and for pain management because of its
low cost and apparent good efficacy and safety history (Pettifer &
Dyson, 2000). In addition to use in mammals, hydromorphone anal-
gesic efficacy has been validated in red‐eared slider turtles (Mans,
Lahner, Baker, Johnson, & Sladky, 2012). It is also an accepted
alternative to morphine because it does not cause histamine release
after i.v. administration (Pettifer & Dyson, 2000; Smith, Yu, Bjorling,
& Waller, 2001).
Despite the rising popularity of hydromorphone in reptile medi-
cine in the USA, reptile formularies do not contain dosing recommen-
dations for analgesic regimens in reptiles. Doses are often adjusted
based on pharmacokinetic and pharmacodynamics principles known
from domestic animals (Sladky, Mader, & Divers, 2014). Pharmacoki-
netic data from studies indicate a large degree of variation between
species. The half‐life in cats, macaques, kestrels and dogs is 98.9,
142, 75 and 60min, respectively (Wegner, Robertson, Kollias‐Baker,
Sams & Muir, 2004; KuKanich, Hogan, Krugner‐Higby & Smith,
2008; Kelly, Pypendop & Christe, 2014; Guzman Sanchez‐Migallon,
KuKanich, Drazenovich, Olsen & Paul‐Murphy, 2014). Clearance is
24.6, 37.7, 62.3 and 60mL/min/kg in cats, macaques, kestrels and
dogs. (Guzman Sanchez‐Migallon et al., 2014; Kelly et al., 2014;
KuKanich et al., 2008; Wegner et al., 2004), while the volume of dis-
tribution at steady state is 2957, 4062, 1164 and 4410mL/kg and the
area under the curve is 4079, 1993, 3508 and 7350mL/min/kg in
cats, macaques, kestrels and dogs, respectively (Guzman Sanchez‐
Migallon et al., 2014; Kelly et al., 2014; KuKanich et al., 2008;
Wegner et al., 2004). The lack of pharmacokinetic data for analgesic
agents in reptiles makes it impossible to determine appropriate doses,
dosing intervals and safety, hampering the appropriate selection and
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use of analgesics in clinical practice. As such, it is difficult to recom-
mend effective and safe dosing intervals for reptiles. Owing to the
large degree of variation in metabolism, pharmacokinetic parameters
must be established for each species.
There have been some methods reported for the determination of
hydromorphone in human plasma which involved radioimmunoassay
(Lee et al., 1991), high‐performance liquid chromatography using elec-
trochemical detection (Wetzelsberger, Lucker, & Erking, 1986;
Bouquilion, Freeman, & Moulin, 1992; Guedes, Papich, Rude & Rider,
2008) and high‐performance liquid chromatography tandem mass
spectrometry (MS) (Chen, Hanson, Jiang, & Naidong, 2002; Coles,
Kushnir, Nelson, McMillin, & Urry, 2007; Dahn, Gunn, Kriger, & Terrell,
2010; Kelly et al., 2014; KuKanich et al., 2008; Musshoff, Trafkowski,
Kuepper, & Madea, 2006; Naidong et al., 2000; Wegner et al., 2004).
The radioimmunoassay method (Lee et al., 1991) lacks selectivity and
requires the use of radioactivity, which requires a license and can be
costly to dispose of, and a large volume of plasma. The electrochemi-
cal detection methods require large sample volumes, have poor recov-
ery and are not as sensitive (Wetzelsberger et al., 1986, Bouquilion
et al., 1992, Guedes et al., 2008).
Many of the LC‐MS methods use large sample sizes and have
more complex time‐consuming extractions. The methods used in
the studies by Kelly et al. (2014) and KuKanich et al. (2008)
required larger sample sizes (0.5 and 1mL) and were not as accu-
rate or precise. The method used by Kelly et al. (2014) does have
a lower LOQ (0.1 ng/mL) but they used a triple quadrupole detector
and a larger sample size to obtain the value. One method (Chen
et al., 2002) requires the use of a robotic liquid handler which is
costly and may not be available in many laboratories. It also has
poor recovery while another method (Musshoff et al., 2006)
requires cannula cleaning for each sample during the extraction
phase, which is time consuming. The method developed by Coles
et al. (2007) is a complicated procedure that requires the number
of drops per second passing through the solid‐phase extraction car-
tridge to be controlled and monitored. In the method by Wegner
et al. (2004) they used a 0.05mL sample; however, a 30% variation
in concentration was acceptable and no LOQ, recovery, accuracy or
precision data was listed. The Guzman Sanchez‐Migallon et al.
(2014) method had a smaller sample size (0.05mL) but used only
three replicates, not five, for validation and used a different plasma
than the actual sample for the validation process. The method
developed by Naidong et al. (2000) used normal‐phase high‐
performance liquid chromatography MS to improve sensitivity and
peak shape; however, that type of chromatography is not com-
monly used in many laboratories. By optimizing chromatography
conditions hydromorphone can be detected using reverse‐phase
chromatography.
The aim of this paper is to describe a simple, sensitive and accu-
rate method for extracting hydromorphone from small‐volume
plasma samples. This method has been successfully applied to
bearded dragon samples analyzed at the author's institution and
should be applicable to other species. It could be useful to those
investigators dealing with small sample volumes, particularly when
conducting pharmacokinetic studies that require multiple sampling
from the same animal.
2 | EXPERIMENTAL
2.1 | Chemicals and standards
Hydromorphone and naltrexone (Figure 1) were purchased from US
Pharmacopeia (Rockville, MD, USA). Both chemicals were >99%
purity. All other mass spectrometry grade chemicals and solvents were
purchased from Fisher Scientific (Pittsburg, PA, USA).
Stock solutions of hydromorphone (100 μg/mL) and naltrexone
(100 μg/mL), which is the internal standard, were prepared in metha-
nol. Dilutions in methanol were prepared to produce 0.01, 0.1 and
1 μg/mL working stocks. Solutions were aliquoted into separate vials
to prevent evaporation and cross‐contamination. All solutions were
stored at 4°C. By comparing standard areas over time it was deter-
mined that they were stable for a minimum of 6 months.
For preparation of calibration standards and quality control sam-
ples, appropriate aliquots of the working stock solutions were placed
in tubes, evaporated to dryness with nitrogen and then dissolved in
100 μL of untreated lithium heparin bearded dragon plasma. The
plasma was obtained from drug‐free healthy animals. The final con-
centrations were 1, 2.5, 5, 10, 25, 50, 100, 250 and 500 ng/mL for cal-
ibration standards and 3.5, 15, 35, 75, 150 and 350 μg/mL for quality
control samples. Calibration standards and control samples were
treated identically to samples. Linearity was assessed by linear regres-
sion analysis. The calibration curve had a correlation coefficient of
≥0.99. The acceptance criterion for each back‐calculated standard
and quality control concentration was 15% deviation from the nominal
value except for the lower limit of quantification (LLOQ), which was
set at 20%.
2.2 | Chromatographic conditions and apparatus
The chromatography system consisted of a 2695 separation module
and an Acuity QDa single‐quadrupole mass detector (Waters, Milford,
MA, USA). Separation was achieved on an Atlantis T3 column
(4.6 × 150mm, 3 μm) preceded by a 3 μm Atlantis T3 guard column.
The mobile phase was a mixture of (A) water with 0.1% formic acid
and (B) acetonitrile with 0.1% formic acid (91:9). The mixture was
pumped at a starting gradient of 91% A and 9% B and held for
4min, and then was adjusted to 85% A and 15% B over 6min, and
back to initial conditions over 3min. The flow rate was 0.70mL/min,
and the column temperature was 30°C. The compounds were
detected by positive selected ion recording. The scan rate was 2
points/s, gain 1, capillary voltage 0.6 kV, cone voltage 12, ion source
temperature 150°C and probe temperature 600°C. Nitrogen was used
FIGURE 1 Structures for hydromorphone and naltrexone
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as the nebulizing gas. Hydromorphone was detected at 286.10m/z
and naltrexone was detected at 342.41m/z.
2.3 | Sample preparation
Hydromorphone was extracted from plasma samples using a solid‐
phase extraction method with Oasis HLB cartridges (Waters, Milford,
MA, USA). Briefly, previously frozen plasma samples were thawed
and vortexed and 100 μL was transferred to a 13 × 100mm glass
tube then 60 μL of internal standard (0.1 μg/mL naltrexone) was
added. Three hundred microliters of water–methanol (65:35) was
added and tubes were vortexed and allowed to stand for 3min, and
then centrifuged for 15min at 1020g. The supernatant was added
to a prewet Oasis 1 cm3 cartridge (1 mL methanol, 1 mL of water)
and washed with 1mL of 3% methanol in water. Samples were eluted
with 1.0 mL of 2% formic acid in acetonitrile–methanol (40:60) and
then evaporated to dryness with nitrogen gas. Samples were
reconstituted in 250 μL of mobile phase and 60 μL injected into the
HPLC system.
3 | RESULTS AND DISCUSSION
3.1 | Method development and optimization
We wanted to develop a simple, straightforward method that would
be effective with small volume samples. Several organic solutions and
mixtures were tested during optimization of the extraction proce-
dure, including acetonitrile, methanol, trichloroacetic acid, ethyl ace-
tate, hexane, and methylene chloride. All were found to produce
FIGURE 2 Chromatograms for
hydromorphone in bearded dragons. (a) A
blank bearded dragon sample; (b) a 25 ng/mL
spiked plasma standard; and (c) a plasma
sample from a bearded dragon 1 h after an
0.5mg/kg subcutaneous dose of
hydromorphone was administered
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lower recoveries compared to the SPE technique with Oasis HLB
cartridges.
During the development of the SPE technique several different
cartridges were examined besides the Oasis HLB (Waters, Milford,
MA, USA), including Strata‐X, Strata‐XA (Phenomenex, Torrance,
CA, USA) and Sep pak plus (Waters, Milford, MA, USA). Use of
Oasis HLB cartridges, with a hydrophilic–lipophilic balanced copol-
ymer, enabled high recoveries for both hydromorphone and
naltrexone; all others had very low recoveries or poor peak resolu-
tion. Once an appropriate cartridge was selected we also looked at
various wash solution combinations, including 1, 3, 5 and 7% meth-
anol in water. The 5 and 7% solutions caused a decrease in recov-
ery and the 1% solution produced an eluent that when re‐dissolved
could not be injected into the system because of particulates. The
3% solution was found to produce the greatest recovery with the
best peak resolution. The elution composition was part of a stan-
dard protocol recommended by the manufacturer which worked
well for the plasma extraction. The amount was increased from
300 μL twice to 500 μl twice. This increased the recovery by
roughly 15%.
3.2 | Method validation
3.2.1 | Selectivity
For specificity testing, untreated plasma from bearded dragons was
prepared in the same manner as study samples and no endogenous
components interfered with elution of the compounds of interest.
Six different blank samples were used in the pre‐validation process
and a blank sample from each animal was included in the analysis.
The elution chemicals were also checked for possible chromatogram
interference. Figure 2 illustrates selected ion recording chromato-
grams of (a) a blank bearded dragon sample, (b) a 25 ng/mL spiked
plasma standard and (c) a plasma sample from a bearded dragon 1 h
after subcutaneous administration of a 0.5mg/kg dose of
hydromorphone. The retention times in plasma for hydromorphone
and naltrexone were 4.60 and 10.50min in bearded dragons, respec-
tively. Drugs that could be used in combination with hydromorphone
in treatment protocols include meloxicam, dexmedetomidine, keta-
mine and/or midazolam. These drugs did not interfere with the analy-
sis of hydromorphone.
3.2.2 | Linearity, accuracy and precision
The plasma peak ratio (area of hydromorphone divided by the internal
standard area) vs the concentration was plotted and produced a linear
curve for the concentration range used (1–500 ng/mL) with a correla-
tion coefficient of 0.9992. A typical equation for the calibration curve
was y = 0.0081x + 0.0020 (Table 1) where y represents the peak area
ratio of hydromorphone to internal standard and x represents the
plasma concentration of hydromorphone in nanograms per milliliter.
Intra‐ and inter‐day assay coefficients of variation (CV) for plasma
spiked with specific concentrations of hydromorphone ranged from
1.2% to 9.3%. The precision was found to be well below the set
±15% for all quality control samples as shown in Tables 1 and 2.
3.2.3 | Recovery, LLOQ
The recovery (Table 3) of hydromorphone from spiked plasma was
determined by comparing the extracted areas with the directly
injected analyte areas and ranged from 88 to 99%. The relative stan-
dard deviation was <10% for all values. The recovery of the internal
standard was 92% and its relative standard deviation was 2.1%. The
use of naltrexone as an internal standard corrects for the intra‐ and
inter‐day assay variability in the assay. The LLOQ was 1 ng/mL, which
represents a peak ~5 times baseline noise. The LLOQ is more than
adequate for use in pharmacokinetic studies. If a lower LLOQ is












3.5 3.5 ± 0.21 100 5.9
15 15 ± 0.91 100 6.1
35 33 ± 3.08 94 9.2
75 72 ± 3.56 96 5.0
150 157 ± 9.13 105 5.8
350 354 ± 4.1 101 1.2
Assay linearity (n = 5)
Mean ± SD CV (%)
y‐Intercept 0.0020 ± 0.0001 5.0
Slope 0.0081 ± 0.0005 6.1
r2 0.9992 ± 0.0002 0.02
SD, Standard deviation; n, number of samples; CV, coefficient of variation.










3.5 3.4 ± 0.17 99 5.2
15 15 ± 1.08 100 7.1
35 36 ± 1.41 103 4.0
75 74 ± 6.92 99 9.3
150 152 ± 6.49 101 4.3
350 353 ± 10.38 101 2.9
SD, Standard deviation; n, number of days; CV, coefficient of variation.
TABLE 3 Recovery for hydromorphone in plasma and (n = 5)







n, Number of days.
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needed, the sample size could be increased. The lower limit of detec-
tion was 0.5 ng/mL, which represents a peak ~3 times baseline noise.
3.3 | Stability
Testing of the short‐term stability of the quality control standards
indicated that there was a 3% loss of hydromorphone after 24 h in
the autosampler and 14% drug loss after 24 h in the refrigerator at
4°C. Therefore, if there were a power or equipment failure, samples
could be reanalyzed, especially if they were not refrigerated. Samples
in our studies were thawed once and analyzed; however, there was no
loss of drug after three freeze–thaw cycles.
4 | CONCLUSION
In conclusion, this analytical procedure was validated in terms of
recovery, linearity, LLOQ, precision and accuracy. The limit of quanti-
fication and recovery are more than adequate for use in pharmacoki-
netic studies. Our results indicate that this HPLC procedure is a
reproducible method that provides consistent quantification of
hydromorphone in plasma. The addition of naltrexone as an internal
standard also allows for the correction of intra‐ and inter‐assay vari-
ability. This method has been used successfully to determine
hydromorphone concentrations in plasma samples at this institution.
Figure 3 is a representative concentration–time profile from a
hydromorphone pharmacokinetic study conducted in bearded dragons
after receiving a 0.5mg/kg subcutaneous dose of hydromorphone.
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